Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma

Abstract The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2017-08-01
Series:Journal for ImmunoTherapy of Cancer
Assuntos:
Bladder cancer
Immunotherapy
Guidelines
Consensus statement
Acceso en liña:http://link.springer.com/article/10.1186/s40425-017-0271-0
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
Cargando...

Títulos similares